FDA
-
-
-
-
-
-
-
UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduced countable motor seizure frequency in CDKL5 deficiency disorder
-
-
-
-
-
-
-
UCB and Domino Data Lab Collaborate to Modernize Statistical Computing Environment in Life Sciences
-
-
-
-
-
-
-
UCB Presents New Data on Impact and Burden of Epilepsy at 2024 American Epilepsy Society (AES) Annual Meeting
-
-
-
-
-
-
-
UCB Launches Dravet Syndrome Sound of Profound Moments: Family Video Project
-
-
-
-
-
-
-
UCB presents new data about the real-world experience of FINTEPLA® (fenfluramine) and rare epilepsy syndromes at 2023 American Epilepsy Society (AES) Annual Meeting
-
-
-
-
-
-
-
UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023
-
-
-
-
-
-
-
Bimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeks
-
323,577 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

